期刊
ONCOLOGY LETTERS
卷 11, 期 4, 页码 2934-2940出版社
SPANDIDOS PUBL LTD
DOI: 10.3892/ol.2016.4300
关键词
hinokitiol; vasculogenic mimicry; breast cancer stem; progenitor cells; epidermal growth factor receptor
类别
资金
- Chung Shan Medical University
- Ditmanson Medical Foundation Chia-Yi Christian Hospital (Taichung, Taiwan) [CSMU-CYC-102-01]
- Ministry of Science and Technology in Taiwan [NSC-101-2314-040-015-MY2, MOST-103-2314-B-040-015-MY3]
Hinokitiol, alternatively known as -thujaplicin, is a tropolone-associated natural compound with antimicrobial, anti-inflammatory and antitumor activity. Breast cancer stem/progenitor cells (BCSCs) are a subpopulation of breast cancer cells associated with tumor initiation, chemoresistance and metastatic behavior, and may be enriched by mammosphere cultivation. Previous studies have demonstrated that BCSCs exhibit vasculogenic mimicry (VM) activity via the epidermal growth factor receptor (EGFR) signaling pathway. The present study investigated the anti-VM activity of hinokitiol in BCSCs. At a concentration below the half maximal inhibitory concentration, hinokitiol inhibited VM formation of mammosphere cells derived from two human breast cancer cell lines. Hinokitiol was additionally indicated to downregulate EGFR protein expression in mammosphere-forming BCSCs without affecting the expression of messenger RNA. The protein stability of EGFR in BCSCs was also decreased by hinokitiol. The EGFR protein expression and VM formation capability of hinokitiol-treated BCSCs were restored by co-treatment with MG132, a proteasome inhibitor. In conclusion, the present study indicated that hinokitiol may inhibit the VM activity of BCSCs through stimulating proteasome-mediated EGFR degradation. Hinokitiol may act as an anti-VM agent, and may be useful for the development of novel breast cancer therapeutic agents.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据